Clearbridge Investments LLC Has $317.69 Million Stock Position in Haleon PLC Sponsored ADR $HLN

Clearbridge Investments LLC reduced its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 5.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 31,423,276 shares of the company’s stock after selling 1,924,656 shares during the period. Clearbridge Investments LLC’s holdings in Haleon were worth $317,689,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in HLN. Norges Bank acquired a new position in shares of Haleon during the fourth quarter valued at about $163,529,000. Natixis Advisors LLC grew its holdings in shares of Haleon by 429.8% during the fourth quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock valued at $101,140,000 after buying an additional 8,115,633 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Haleon by 116.7% during the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after buying an additional 6,669,923 shares during the last quarter. Optiver Holding B.V. acquired a new position in shares of Haleon during the third quarter valued at about $45,593,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Haleon by 36.6% during the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after buying an additional 3,207,986 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Up 1.8%

HLN opened at $9.13 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The company’s 50-day moving average is $9.43 and its 200 day moving average is $9.93. Haleon PLC Sponsored ADR has a fifty-two week low of $8.65 and a fifty-two week high of $11.28. The firm has a market capitalization of $40.42 billion, a P/E ratio of 23.40, a PEG ratio of 2.08 and a beta of 0.13.

Haleon (NYSE:HLN) last released its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The firm had revenue of $3.65 billion for the quarter. Research analysts expect that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on HLN shares. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Finally, Argus upgraded shares of Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.